Press Releases Press Releases Keyword Search Year None20232022202120202019201820172016201520142013 22 May '2023 FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients 17 May '2023 XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares 17 Apr '2023 XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Press Releases Keyword Search Year None20232022202120202019201820172016201520142013 22 May '2023 FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients 17 May '2023 XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares 17 Apr '2023 XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
17 Apr '2023 XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
